Lipid-lowering Therapy Individualization

计划入组 75 人 · 首次发布于 2018 年 7 月 27 日

Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy

首次发布于 2013 年 6 月 3 日

Plaque Reversal With Early, Aggressive Lipid Lowering Therapy

计划入组 60 人 · 首次发布于 2023 年 3 月 24 日

Lapaquistat

C₃₁H₃₉ClN₂O₈

high-density lipoprotein delipidation therapy (Lipid Sciences)

BCKDHA mRNA therapy (Moderna)

Lipid Therapeutics GmbH

Germany

METABOLIC THERAPY, INC.

United States

Everads Therapy Ltd.

Israel

Daiichi Sankyo Initiates Development of Triple-Combination Lipid-Lowering Tablet to Address Treatment Gaps

Triglyceride-Lowering Drug Olezarsen Fails to Reduce Arterial Plaque Despite 60% Triglyceride Reduction

FDA Accepts Review of Lerodalcibep for LDL Cholesterol Reduction